11 minute read
Apr. 24, 2023

A Potential Next Best-In-Class Allosteric TYK2 Inhibitor Exhibits Strong Ph. II Results for Plaque Psoriasis

TAK-279 (NDI-034858)

oral, once-daily, allosteric TYK2 inhibitor Ph. IIb for moderate-to-severe plaque psoriasis FEP+ supported VLS + core hopping w/ TYK2-JH2 Xtal structure Press release, March 18, 2023 Nimbus Therapeutics, MA / Takeda, JP


MOTY Nominees

Molecule of the Year